Daiichi Sankyo Company, Limited (DSNKY) Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day Transcript
Summarize this article with:
SA Transcripts157.37K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Daiichi Sankyo Company, Limited (DSNKY) Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day December 15, 2025 5:30 PM EST Company Participants Kentaro Asakura - Corporate Officer, Head of Corporate Communications Deptt, Global Corporate Planning & MngmtHiroyuki Okuzawa - President, CEO & Representative DirectorKen Takeshita - Head of Research & Development UnitJoseph Keller - President & CEOHiroto Kashiwase - Executive Officer & Head of Technology DivisionYuki Abe - Corporate Officer, Head of R&D Division and Head of Research Function Conference Call Participants Hidemaru Yamaguchi - Citigroup Inc., Research DivisionKazuaki Hashiguchi - Daiwa Securities Co. Ltd., Research DivisionSeiji Wakao - JPMorgan Chase & Co, Research DivisionMatsubara - Nomura Securities Co. Ltd., Research DivisionShinichiro Muraoka - Morgan Stanley, Research DivisionStephen Barker - Jefferies LLC, Research DivisionMiki Sogi - Sanford C. Bernstein & Co., LLC., Research DivisionTony Ren - Macquarie ResearchMichael Nedelcovych - TD Cowen, Research Division Presentation Kentaro AsakuraCorporate Officer, Head of Corporate Communications Deptt, Global Corporate Planning & Mngmt [Interpreted] Thank you for your participation. We will now begin Daiichi Sankyo's Science and Technology Day 2025. I am Asakura from Corporate Communications, your moderator today. First, regarding languages. This briefing will be conducted in Japanese and English. Simultaneous interpretation is available. Please click the Interpretation icon at the bottom of your Zoom screen and select either Japanese, English or original audio . If you select original audio, you will hear the original audio. The Zoom screen and Live stream will display the English presentation materials. The Japanese and English presentation materials are available on our corporate website's IR library under the IR presentation materials page. Please download and view them as needed. Today's speakers are Okuzawa, President and CEO; Takeshita, Head of Global R&D; Ken Keller, Director and Head of Global Oncology business; Kashiwase, Head of Global Technology; and Abe, Head of Global